Jon wang cstone
Nettet13. apr. 2024 · Jon Wang. @_JonWang. ·. one of the most common mistakes first-time founders make is being too focused on building cool stuff & sexy product vision--this is what we're exposed to from media the second time around, they focus hard on customers and GTM, oftentimes before writing a single line of code. Jon Wang Retweeted. Nettet19. okt. 2024 · Dr. Jon Wang. Wang joined CStone Pharmaceuticals in June 2024, as the Senior Vice President, Chief Scientific Officer. He is responsible the scientific development of CStone’s product portfolio and technology platforms of interest, and providing general scientific leadership from discovery to IND.
Jon wang cstone
Did you know?
NettetDr€Jon Wang, CStone's Chief Scientific Officer, noted: "The aberrant activation CDK4/6 was observed across various tumour types, suggesting CS3002's potential utility in the treatment of breast cancer and a variety of other solid tumours. NettetCStone Pharmaceuticals has 5 employees at their 1 location and $410 m in total funding,. See insights on CStone Pharmaceuticals including office locations, competitors, revenue, financials, ... Jon Wang, Chief Scientific Officer. Linkedin; LocationsView all. 1 location detected.
NettetNumber of Employee Profiles 4. CStone Pharmaceuticals has 4 current employee profiles, including CEO Frank Jiang. Frank Jiang CEO. Jason Yang Chief Medical Officer. Jon Wang Chief Scientific Officer. Nettet22. aug. 2024 · Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make …
Nettet19. okt. 2024 · Dr. Jon Wang. Wang joined CStone Pharmaceuticals in June 2024, as the Senior Vice President, Chief Scientific Officer. He is responsible the scientific development of CStone’s product portfolio and technology platforms of interest, and providing general scientific leadership from discovery to IND. Nettet"CS1003 is a differentiated anti-PD-1 monoclonal antibody which allows us to quickly evaluate efficacy for combination therapies in animal models at the preclinical stage, …
NettetSUZHOU, China, Aug. 23, 2024 /PRNewswire/ -- CStone completes registration filing for the Phase I trial of CDK4/6 inhibitor CS3002 in Australia and will soon initiate the study
NettetBeing developed by CStone, CS3002 is a selective inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6). Inducing cell cycle arrest of tumor cells through the selective inhibition of CDK4/6, CS3002 has demonstrated high therapeutic potential for combination with endocrine therapy or immune checkpoint inhibitor therapy in various solid tumors. divided meal containersNettetDr. Jon Wang, CStone’s Chief Scientific Officer, noted: “The aberrant activation CDK4/6 was observed across various tumor types, suggesting CS3002’s potential utility in the … craft by the poundNettetDr. Jon Wang, CStone’s Chief Scientific Officer, noted: "The aberrant activation CDK4/6 was observed across various tumor types, suggesting CS3002’s potential utility in the treatment of breast cancer and a variety of other solid … craft cabinet mounted portableNettet19. okt. 2024 · Dr. Jon Wang Wang joined CStone Pharmaceuticals in June 2024, as the Senior Vice President, Chief Scientific Officer. He is responsible the scientific … divided non stick pancraft cabinet fold outNettetDr. Jon Wang, CStone’s chief scientific officer, noted: “The aberrant activation CDK4/6 was observed across various tumor types, suggesting CS3002’s potential utility in the treatment of breast cancer and a variety of other solid tumors. Recent studies have shown that, in addition to inducing cell cycle arrests of tumor cells, divided paper plates amazonNettetDr. Jon Wang, MD is a board certified orthopedic surgeon in Tucson, Arizona. He is currently licensed to practice medicine in Arizona. He is affiliated with Northwest … divided opinion podcast